最新ニュース PDD Holdings (NASDAQ:PDD) 株価情報

PDD Holdings

PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.

PDD Holdings Inc. - American Depositary Shares

PDD Holdings Inc

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $2.46 per share which beat the analyst consensus estimate of $2.38 by 3.36 percent. This is a 6.49 percent increase over earnings of $2.31 per share from the same period last year. The company reported quarterly sales of $13.34 billion which beat the analyst consensus estimate of $12.92 billion by 3.25 percent. This is a 8.39 percent increase over sales of $12.31 billion the same period last year.

Earnings

Earnings Beats

News

ABBV

AbbVie Q1 Adj. EPS $2.46 Beats $2.38 Estimate, Sales $13.34B Beat $12.92B Estimate

Two million dollars might sound like an iron-clad nest egg, but where you spend your golden years can make it evaporate or endure for decades.
What Happened: A new GOBankingRates <a href="https://www.gobankingrates.com/retirement/planning/how-long-2-million-will-last-in-retirement-in-every-state/">study</a> finds the same bankroll plus average Social Security checks would last 72 years in West Virginia, yet only 23 years in Hawaii — a three-fold swing driven largely by housing costs.
Analysts tallied typical retiree expenses for groceries, health care, transportation, utilities and shelter using the Bureau of Labor Statistics' 2023 Consumer Expenditure Survey, then adjusted those figures with the Missouri Economic Research and Information Center's cost-of-living index for each state.
Low-cost Appalachia dominates the longevity leaderboard. After West Virginia, Kansas stretches $2 million for 69 years, while Mississippi, Oklahoma and Alabama hover between 66 and 68 years. Retirees in these states can expect post-Social-Security budgets near $30,000 a year, leaving plenty of cushion even with modest investment returns.
See also: <a href="https://www.benzinga.com/general/25/04/45004194/dave-ramsey-calls-social-security-a-4-return-but-this-wealth-expert-says-thats-a-dangerous-oversimplification-that-could-cost-thousands">Dave Ramsey Calls Social Security A &#8216;-4% Return&#8217; —But This Wealth Expert Says That&#8217;s A Dangerous Oversimplification That Could Cost Thousands</a>
At the other extreme, three states with sky-high real-estate tabs would burn through the same savings in roughly 30 years or less. Hawaii's retirees face annual outlays of nearly $88,000 after Social Security. California and Massachusetts trail close behind at about $64,000 and $65,000, respectively, shortening the portfolio's lifespan to 31 years.
The Bottom Line: The gap shows how sharply shelter costs skew retirement math. In coastal states with dense urban centers, housing alone can run $30,000 more per year than in the heartland, the report shows.
Although hitting $2 million is a reach for most — just <a href="https://www.ebri.org/retirement/content/the-status-of-american-families%27-accumulations-in-individual-account-retirement-plans--an-analysis-of-the-2022-survey-of-consumer-finances">1.8 percent of households</a> have amassed that much, according to the Employee Benefit Research Institute — the analysis suggests even a <a href="https://www.benzinga.com/personal-finance/24/11/42070971/suze-orman-warns-3-million-isnt-enough-for-retirement-even-at-a-mere-3-withdrawal-rate-she-says-you-need-10-million-or-more">seven-figure balance can be fragile</a> in pricey ZIP codes. Financial planners say the findings are a reminder to weigh state taxes, health-care access and, above all, living costs before <a href="https://www.benzinga.com/real-estate/24/09/40728965/can-you-guess-which-state-was-just-ranked-as-1-best-place-to-retire-hint-its-not-florida">picking a retirement haven</a>.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/personal-finance/25/04/44969001/65-year-old-with-110k-saved-asks-if-he-can-retire-in-7-years-dave-ramsey-says-you-have-no-money-and-tells-him-to-stop-401k-contributions">65-Year-Old With $110K Saved Asks If He Can Retire in 7 Years — Dave Ramsey Says &#8216;You Have No Money&#8217; and Tells Him to Stop 401(k) Contributions</a>

Personal Finance

General

$2 Million Nest Egg Could Buy You Seven Decades — Or Barely Two: Best And Worst States For Retirement Longevity

Barrington Research analyst Vincent Colicchio maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Outperform and maintains $75 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on WNS (Hldgs), Maintains $75 Price Target

Piper Sandler analyst Clarke Jeffries maintains Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Overweight and lowers the price target from $747 to $708.

Piper Sandler Maintains Overweight on Tyler Technologies, Lowers Price Target to $708

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that the first patient has been administered both the first protein dose and the 177Lu-DOTA imaging dose in its Phase 1 clinical trial evaluating the Company's Self-Assembly and Disassembly ("SADA") Pre-targeted Radioimmunotherapy ("PRIT") platform for the treatment of patients with relapsed or refractory non-Hodgkin Lymphoma (r/r NHL). This Phase 1 trial (Trial 1201) is a dose-escalation, open-label, single-arm, multi-center trial investigating the safety and tolerability of the CD38-SADA: 177Lu-DOTA Drug Complex.
Trial 1201 is designed to investigate the pre-targeted delivery of the CD38-SADA protein that binds with high affinity to lymphoma cells, followed by the administration of a radioactive 177Lu-DOTA payload to selectively target the tumor-bound CD38-SADA molecules while minimizing radiation to normal tissues. Part A of the trial is CD38-SADA dose escalation with fixed 177Lu-DOTA payload doses to explore the optimal CD38-SADA protein dose and interval between the SADA protein administration and the payload. The primary endpoints of Part A include tumor imaging and occurrence of dose limiting toxicities in the dose limiting toxicities (DLT) evaluation period.
 &nbsp;
 &nbsp;

YMAB

Y-mAbs Says First Patient Administered First Protein Dose And 177Lu-DOTA Imaging Dose In Phase 1 Clinical Trial Evaluating CD38-SADA Pre-Targeted Radioimmunotherapy In r/r NHL

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $72 price target.

Reiteration

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target

Barrington Research analyst Gary Prestopino maintains Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) with a Outperform and maintains $16 price target.

Barrington Research Maintains Outperform on Stoneridge, Maintains $16 Price Target

Biotech

Health Care

PLRZ

Polyrizon Announced Preliminary Safety Study For A Formulation Of Its PL-14 Allergy Blocker, Conducted On Fully Differentiated Human Nasal Tissue Using The Mucilair Model, The Study Demonstrated Strong Local Tolerability

Barrington Research analyst Gary Prestopino maintains Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) with a Outperform and maintains $220 price target.

Barrington Research Maintains Outperform on Standex International, Maintains $220 Price Target

Barrington Research analyst Gary Prestopino maintains Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) with a Outperform and maintains $410 price target.

Barrington Research Maintains Outperform on Kadant, Maintains $410 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) with a Buy and maintains $5 price target.

TNYA

HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target

Barrington Research analyst Alexander Paris maintains H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) with a Outperform and maintains $70 price target.

Barrington Research Maintains Outperform on H&R Block, Maintains $70 Price Target

SHANGHAI, China, April 25, 2025 (GLOBE NEWSWIRE) -- Pony AI Inc. ("Pony.ai" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>), a global leader in achieving large-scale commercialization of autonomous mobility, announced a strategic partnership with Tencent Cloud and Smart Industries Group ("CSIG", or the "Tencent Cloud"), the cloud business of Tencent Holding Limited (HKEX: 00700, "Tencent"), a world-leading Internet and technology company in China, to jointly advance autonomous driving technology and accelerate the commercialization of Robotaxi services. This partnership will amplify Pony.ai's cutting-edge autonomous driving technology by leveraging Tencent's ecosystem — including Weixin,&nbsp;Tencent Maps and its robust cloud computing, big data and AI infrastructure. It marks a significant step forward for Pony.ai's ongoing journey toward large-scale commercialization.
 &nbsp;

PONY

Pony AI Partners With Tencent Cloud And Smart Industries Group To Jointly Advance Autonomous Driving Technology, Accelerate Commercialization Of Robotaxi Services

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) reported quarterly earnings of $1.86 per share which missed the analyst consensus estimate of $2.77 by 32.85 percent. This is a 44.97 percent decrease over earnings of $3.38 per share from the same period last year. The company reported quarterly sales of $787.58 million which missed the analyst consensus estimate of $810.94 million by 2.88 percent. This is a 4.35 percent increase over sales of $754.77 million the same period last year.

Earnings Misses

SAIA

Saia Q1 EPS $1.86 Misses $2.77 Estimate, Sales $787.58M Miss $810.94M Estimate

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) affirms FY2025 GAAP EPS guidance from $24.05-$25.85 to $24.05-$25.85 vs $24.97 analyst estimate. Affirms FY2025 sales outlook from $72.80 billion-$75.80 billion to $72.80 billion-$75.80 billion vs $74.63 billion estimate.

Guidance

HCA Healthcare Affirms FY2025 GAAP EPS Guidance of $24.05-$25.85 vs $24.97 Est; Affirms FY2025 Sales Guidance of $72.80B-$75.80B vs $74.63B Est

Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) affirms FY2025 sales outlook from $3.23 billion-$3.43 billion to $3.23 billion-$3.43 billion vs $3.34 billion estimate.

PHIN

Phinia Affirms FY2025 Sales Guidance of $3.23B-$3.43B vs $3.34B Est

Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.01 by 6.93 percent. This is a 12.96 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $796.00 million which missed the analyst consensus estimate of $814.39 million by 2.26 percent. This is a 7.76 percent decrease over sales of $863.00 million the same period last year.

Phinia Q1 Adj. EPS $0.94 Misses $1.01 Estimate, Sales $796.00M Miss $814.39M Estimate

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported quarterly earnings of $6.45 per share which beat the analyst consensus estimate of $5.76 by 11.98 percent. This is a 20.34 percent increase over earnings of $5.36 per share from the same period last year. The company reported quarterly sales of $18.32 billion which beat the analyst consensus estimate of $18.26 billion by 0.35 percent. This is a 5.66 percent increase over sales of $17.34 billion the same period last year.

HCA Healthcare Q1 Adj. EPS $6.45 Beats $5.76 Estimate, Sales $18.32B Beat $18.26B Estimate

Needham analyst Scott Berg reiterates SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and maintains $210 price target.

SPSC

Needham Reiterates Buy on SPS Commerce, Maintains $210 Price Target

In a move indicating a possible easing of trade tensions, China has reportedly started to exempt some U.S. imports from high tariffs and is proactively seeking feedback from companies on other key items they want excluded from them.
What Happened: Companies in China say that they have been approached by officials to identify U.S. goods that are essential and difficult to replace, reported Reuters.
Some pharmaceutical imports and aerospace parts like engines and landing gear have reportedly already been excluded from the 125% tariffs. American Chamber of Commerce in China President Michael Hart confirmed that multiple member firms, especially in pharma, have not had to pay tariffs.
See Also: <a href="https://www.benzinga.com/25/04/45003278/flexport-ceo-joins-galloway-tariff-workarounds-and-fraud-will-force-trump-to-walk-back-on-trade-war-with-china">Trump Will Be First To &#8216;Blink&#8217; In China Trade War, Flexport&#8217;s Ryan Petersen Tells Scott Galloway: &#8216;The Market Finds A Way&#8217; Amid Tariff Workarounds, Fraud Surge</a>
Why It Matters: The exemptions are being made as both Beijing and Washington demonstrate <a href="https://www.benzinga.com/markets/25/04/44942449/trump-pledges-substantial-cut-in-china-tariffs-but-refuses-to-make-it-zero-if-they-dont-make-a-deal-we-will-set-the-deal">noticeable signs of de-escalation</a> in a trade war that has upset markets and stressed global supply chains. "As a quid-pro-quo move, it could provide a potential way to de-escalate tensions," said Alfredo Montufar-Helu of the Conference Board's China Center.
However, he said that neither side seems keen to make the first formal move to make a deal. China&#8217;s Ministry of Commerce <a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis">denied rumors</a> of trade discussions with the U.S. on Thursday. 
While China's leadership has not made any official statement about the exemptions, the move seems to be targeted at shielding domestic industries from even more pressure. With major sectors still reliant on American inputs— ranging from ethane to specialty drugs—the exemptions may be just the beginning. "For irreplaceable goods, there's clear interest in unilateral exemptions," Montufar-Helu observed.
Read Next: <a href="https://www.benzinga.com/25/04/44999388/charlie-munger-once-slammed-the-idea-of-escalating-tariffs-in-the-us-china-trade-war-calling-it-massively-stid-heres-why-he-believed-both-sides-should-get-used-to-feeling-roughed-up-and-strike-a-deal">Charlie Munger Once Observed That A Full-Scale US-China Tariff War Was &#8216;Massively Stupid&#8217;: The Legendary Investor Didn&#8217;t Mind If Both Beijing And Washington Got Bruised Up In Talks Though — Here&#8217;s Why</a>
Image Via Shutterstock

Global

Economics

Markets

China Reportedly Begins Exempting Key US Imports From Tariffs, Including Pharma And Aerospace Parts

Legal

Press Releases

PDD Investors Have Opportunity to Lead PDD Holdings Inc. Securities Fraud Lawsuit with the Schall Law Firm

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PDD Holdings f/k/a Pinduoduo

DEADLINE ALERT for EXTR, PDD, CXM, and SYM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

PDD Holdings to Report Third Quarter 2024 Unaudited Financial Results on November 21, 2024

PDD Holdings Announces Third Quarter 2024 Unaudited Financial Results

Fintech

AI WealthTech company Range Raises $28 Million Series B Led by Cathay Innovation

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology

PDD Holdings to Report Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025

PDD Holdings Announces Fourth Quarter 2024 and Fiscal Year 2024 Unaudited Financial Results

EXTR

HUYA

Amazon.com

Alibaba Group Holding Limited American Depositary Shares each representing eight Ordinary share

Alibaba Gr Hldgs

Baozun

Coupang

Dillard's

1stdibs.com

eBay

Etsy

Global E Online

Groupon

D-Market Electronic Services & Trading - American Depositary Shares

D-MARKET Electronic

Hour Loop

JD.com, Inc. - American Depositary Shares

JD.com

Jumia Technologies AG American Depositary Shares, each representing two Ordinary Shares

Jumia Technologies

Nordstrom

Kohl's

ContextLogic

Macy's

MercadoLibre

MINISO Group Holding Limited American Depositary Shares, each representing four Ordinary Shares

MINISO Group Holding

Ollie's Bargain Outlet Holdings, Inc. - Common Stock

Ollie's Bargain Outlet

QVC Group

Savers Value Village

Vipshop Holdings Limited American Depositary Shares, each representing two ordinary shares

Comments

PDD Holdings

ニュース

最新ニュース PDD Holdings (NASDAQ:PDD) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル